CARDIORENAL METABOLIC SYNDROME.
NOVAPEP IS MODIFYING NVP-202 TO PRODUCE NOVEL PEPTIDE ANALOGS WITH SIGNIFICANTLY IMPROVED CIRCULATING HALF-LIFE - THE NVP-300 SERIES.
NVP-300 Series Lead Candidate in Diabetic Cardiorenal Syndrome
The Lead NVP-300 Candidate will be progressed into a Phase 1 Trial in 2027.
COLITIS PROGRAM
APC has been shown to be effective in vivo in diabetic kidney disease and diabetes-induced atherosclerosis:
-
'Activated Protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.' Isermann et al, Nature Medicine, Nov 2007.
-
'Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular P21 expression.' Al-Dabet et al. Nature Coms, Aug 2022.
-
'IRE1Α induced senescence promotes endothelial barrier dysfunction in diabetes-induced atherosclerosis.' Fatima et al. Atherosclerosis, Aug 2023.
-
'Activated protein C ameliorates diabetes-induced atherosclerosis by sustaining macrophage efferocytosis.' Ambreen et al. Cardiovasc Diabetol, Oct 2025.